Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.

@article{Sgadari2003UseOH,
  title={Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.},
  author={Cecilia Sgadari and Paolo Monini and Giovanni Barillari and Barbara Ensoli},
  journal={The Lancet. Oncology},
  year={2003},
  volume={4 9},
  pages={
          537-47
        }
}
HIV protease inhibitors are antiretroviral drugs that block the enzyme required for production of infectious viral particles. Although these agents have been designed to selectively bind to the catalytic site of HIV protease, evidence indicates that other cellular and microbial enzymes and pathways are also affected. It has been reported that patients treated with highly active anti-retroviral therapy (HAART) containing a protease inhibitor may be at reduced risk of Kaposi's sarcoma (KS) and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 61 CITATIONS, ESTIMATED 49% COVERAGE

Pharmacological management of Kaposi's sarcoma.

  • Expert opinion on pharmacotherapy
  • 2011
VIEW 5 EXCERPTS
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2001
2019

CITATION STATISTICS

  • 2 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 89 REFERENCES

Kaposi ’ s sarcoma associated herpesvirus ( KSHV ) or human herpesvirus 8 ( HHV 8 )

B Ensoli, R Gendelman, P Markham
  • Virus Res
  • 2002

Long-term exposure to lifelong therapies.

  • Journal of acquired immune deficiency syndromes
  • 2002